Gerot Lannach Competitors and Similar CompaniesClear all

Gerot Lannach's competitors and similar companies include APEIRON Biologics, Northwest Biotherapeutics, Ascendis Pharma and Sirnaomics US.

	Gerot Lannach Gerot Lannach is a pharmaceutical company that develops, produces, and sells both branded products and generics.	APEIRON Biologics APEIRON Biologics is a biotech company focused on the discovery and development of cancer immunotherapies.	Northwest Biotherapeutics Northwest Biotherapeutics is a biotechnology company focused on developing and commercializing immunotherapy products to treat cancer.	Ascendis Pharma Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology.	Sirnaomics US Sirnaomics is a biopharmaceutical company developing oncology therapeutics by using RNA interference (RNAi) technology.
Founding Date	Founding Date 1947	Founding Date 2005	Founding Date 1998	Founding Date 2007	Founding Date 2007
Type	Type Private	Type Private	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech clinical research drug development medical records oncology therapy	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Lannach, AT HQ Lannach, AT Wien, AT Sofia, BG Hamburg, DE Budapest, HU Rīga, LV see more	Locations Wien, AT HQ	Locations Bethesda, US HQ	Locations Hellerup, DK HQ Heidelberg, DE Palo Alto, US	Locations Germantown, US HQ Cambridge, US
Employees	Employees 3382% increase	Employees 5	Employees 1721% increase	Employees 1,017	Employees 3211% decrease
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 349.5 m	Valuation ($) 7.7 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $1.4m (FY, 2024)	Revenue (est.) €363.6m (FY, 2024)	Revenue (est.) N/A
Net income	Net income N/A	Net income N/A	Net income ($83.8m) (FY, 2024)	Net income (€378.1m) (FY, 2024)	Net income N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 135.9m	Total funding raised $ 85.8m	Total funding raised $ 162m